Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.

Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.

Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.

Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.

Abstract: A method for treating intact irritated or inflamed skin with a composition comprising at least one Histamine Receptor pathway inhibitor; at least one Lipoxygenase pathway inhibitor; at least one Cyclooxygenase pathway inhibitor and at least one Chemotaxis pathway inhibitor.

Abstract: Methods of developing equations for objectively assigning or predicting an apparent age are disclosed. Advantageously, the equations of objective apparent age may be based on a relatively small number of critical parameters combined in a way that accounts for all or most of the apparent skin aging in a defined population or sub-population. Despite the relatively small data collection requirements, the present invention includes an objective model of apparent age that is useful for evaluation of products, useful for predicting treatment outcomes and useful for predicting the effects of deteriorative factors. The formalization of an Objective Apparent Age Score allows one to identify the biophysical and biochemical parameters that mostly influence an individual's apparent age, and can be used to select specific anti-aging treatments with increased chances of visible success. The Objective Apparent Age Score may also be used to support marketing claims.

Abstract: A method for formulating products to normalize skin or treat irritated or inflamed skin, a method for normalizing skin or treating irritated or inflamed skin for improvement, and compositions therefor.

Abstract: Methods of developing equations for objectively assigning or predicting an apparent age are disclosed. Advantageously, the equations of objective apparent age may be based on a relatively small number of critical parameters combined in a way that accounts for all or most of the apparent skin aging in a defined population or sub-population. Despite the relatively small data collection requirements, the present invention includes an objective model of apparent age that is useful for evaluation of products, useful for predicting treatment outcomes and useful for predicting the effects of deteriorative factors. The formalization of an Objective Apparent Age Score allows one to identify the biophysical and biochemical parameters that mostly influence an individual's apparent age, and can be used to select specific anti-aging treatments with increased chances of visible success. The Objective Apparent Age Score may also be used to support marketing claims.

Abstract: The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme extract can be derived from Exophiala mansonii. The compositions containing the enzyme extract are more effective than are similar compositions containing kojic acid in producing a whitening effect on the skin.

Abstract: A method for formulating products to normalize skin or treat irritated or inflamed skin, a method for normalizing skin or treating irritated or inflamed skin for improvement, and compositions therefor.

Abstract: The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme extract can be derived from Exophiala mansonii. The compositions containing the enzyme extract are more effective than are similar compositions containing kojic acid in producing a whitening effect on the skin.

Abstract: The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme extract can be derived from Exophiala mansonii. The compositions containing the enzyme extract are more effective than are similar compositions containing kojic acid in producing a whitening effect on the skin.

Abstract: The present invention relates to topical skin whitening compositions comprising a whitening effective amount of a black yeast-derived melanin-degrading enzyme extract and a method of preparing the compositions. The compositions provide a whitening effect by degrading melanin on the surface of the skin, the hair and the nails. The enzyme extract can be derived from Exophiala mansonii. The compositions containing the enzyme extract are more effective than are similar compositions containing kojic acid in producing a whitening effect on the skin.

Abstract: The present invention relates to a cosmetic or pharmaceutical composition for topical application to the skin afflicted with rosacea and treated with a retinoid. The composition for treating rosacea comprises an anti-irritating component and several other components for treating rosacea. The other components form a mixture of a salicylic acid, a phytosphingosine, green tea, hinokitiol, gorgonian extract, and polysaccharide. The invention also provides a method for decreasing the irritation on the skin caused by the heightened sensitivity experienced by skin suffering from rosacea. The other components are effective in treating the rosacea condition, but particularly, in treating the telangiectasic symptom of rosacea.

Abstract: The present invention relates to a cosmetic or pharmaceutical composition for topical application to the skin afflicted with rosacea and treated with a retinoid. The composition for treating rosacea comprises an anti-irritating component and several other components for treating rosacea. The other components form a mixture of a salicylic acid, a phytosphingosine, green tea, hinokitiol, gorgonian extract, and polysaccharide. The invention also provides a method for decreasing the irritation on the skin caused by the heightened sensitivity experienced by skin suffering from rosacea. The other components are effective in treating the rosacea condition, but particularly, in treating the telangiectasic symptom of rosacea.

Abstract: The present invention relates to cosmetic or pharmaceutical topical compositions containing at least one cyclic nucleotide having its 2′ hydroxyl group replaced by a hydrogen atom for inhibiting phosphodiesterase activity. The phosphodiesterase inhibitor is in combination with a magnesium buffer and a cosmetically or pharmaceutically acceptable carrier. The invention also includes methods for treating or preventing inflammation or irritation such as is common in the skin disease, atopic dermatitis, which is known to be related to the uncontrolled activity of phosphodiesterase.

Abstract: The present invention relates to cosmetic or pharmaceutical topical compositions containing at least one cyclic nucleotide having its 2′ hydroxyl group replaced by a hydrogen atom for inhibiting phosphodiesterase activity. The phosphodiesterase inhibitor is in combination with a magnesium buffer and a cosmetically or pharmaceutically acceptable carrier. The invention also includes methods for treating or preventing inflammation or irritation such as is common in the skin disease, atopic dermatitis, which is known to be related to the uncontrolled activity of phosphodiesterase.

Abstract: The present invention relates to self-tanning compositions comprising an effective amount of DHA in combination with an effective amount of propolis extract. The compositions provide self-tanning compositions which can produce a tan with enhanced coloration. The self-tan produced using the compositions of the present invention is more natural looking. In another embodiment of the present invention, the compositions comprise DHA combined with caffeic acid phenethyl ester.

Abstract: The invention relates to composition having enhanced biological activity, the compositions comprising at least one structured water. In particular, the compositions contain a combination of I and S waters and a biologically active agent, in which the activity of the agent is increased relative to its activity in a non-structured water composition.

Abstract: The invention relates to topical cosmetic or pharmaceutical compositions comprising an anti-stinging effective amount of an amino acid selected from the group consisting of an amino butyric acid, glutamine, glycine, and derivatives thereof, or mixtures thereof, as well as methods of reducing or preventing stinging using such compositions.